The Accure Laser System is the next generation light-based platform for the treatment of acne. The Accure Laser is the first 1726nm-based laser platform with both FDA and CE Mark clearances. BOULDER, ...

BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing ...

Please provide your email address to receive an email when new articles are posted on . 10.5% of patients treated with isotretinoin experienced mood changes. 88% of patients experienced symptom ...

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. ・The company said that once daily oral 50 mg Denifanstat ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A rapid improvement in severe acne was observed in patients treated with 12 weeks of trifarotene and ...

Acne vulgaris, better known as acne, is the most common skin condition in the US, according to the American Academy of Dermatology (AAD), affecting up to 50 million Americans annually. About 85% of ...

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial ...

MALVERN, Pa.--(BUSINESS WIRE)--Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...